AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Alector Inc (NASDAQ:ALEC)
1.45 USD
-0.040 2.685%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.49 |
|---|---|
| Change | -0.040 2.685% |
| 52 W H/L (in USD) | 8.900/2.000 |
| EBITDA (in USD) | -177.394M |
| PE Ratio | -- |
| Volume | 132538 |
| Diluted Eps TTM | -1.71 |
| Total Assets (in USD) | 621.827M |
|---|---|
| Total Liabilities (in USD) | 487.669M |
| Revenue TTM (in USD) | 61.508M |
| Cash (in USD) | 74.555M |
| Market Cap (in USD) | 226.224 M |
| Revenue Per Share TTM | 0.661 |
| Gross Profit TTM (in USD) | -76.801M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
415 231 5660
Employees: 241
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Tillman Ulf Gerngross Ph.D. | Co-Founder & Chairman | 1964 |
| 2. | Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director | 1956 |
| 3. | Dr. Sara Kenkare-Mitra Ph.D. | Pres and Head of R&D | 1968 |
| 4. | Mr. Calvin Yu | VP of Fin. | 1976 |
| 5. | Dr. Marc Grasso M.D. | Chief Financial Officer | 1974 |
| 6. | Mr. Peter Heutink Ph.D. | Chief Scientific Officer | NA |
| 7. | Michelle Corral | VP of Communications & Investor Relations | NA |
| 8. | Ms. Danielle Pasqualone J.D., Ph.D. | Gen. Counsel | NA |
| 9. | Erica Jefferson | VP of Communications & Public Affairs | NA |
| 10. | Ms. Clare Hunt M.B.A. | Chief People Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -130.056M | -36.329M | -190.228M | -105.385M | -52.248M |
| Minority Interest | - | - | - | - | - |
| Net Income | -133.31M | -28.014M | -182.963M | -99.811M | -52.248M |
| Selling General Administrative | 61.033M | 55.038M | 59.403M | 35.095M | 11.934M |
| Gross Profit | 133.617M | 207.085M | 21.098M | 21.219M | 27.677M |
| Reconciled Depreciation | 8.472M | 8.315M | 7.265M | 5.574M | 1.019M |
| Ebit | -146.306M | -45.675M | -202.439M | -119.978M | -58.307M |
| Ebitda | -137.834M | -37.36M | -195.174M | -114.404M | -57.288M |
| Depreciation And Amortization | 8.472M | 8.315M | 7.265M | 5.574M | 1.019M |
| Operating Income | -137.834M | -37.36M | -195.174M | -114.404M | -57.288M |
| Other Operating Expenses | 271.451M | 244.445M | 216.272M | 135.623M | 84.965M |
| Interest Expense | -16.25M | 8.315M | 0M | 0M | 0M |
| Tax Provision | 3.254M | - | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | 3.254M | -8.315M | -7.265M | -5.574M | 5.04M |
| Total Revenue | 133.617M | 207.085M | 21.098M | 21.219M | 27.677M |
| Total Operating Expenses | 271.451M | 244.445M | 216.272M | 135.623M | 84.965M |
| Cost Of Revenue | - | - | - | - | 73.031M |
| Total Other Income Expense Net | 7.778M | 1.031M | 4.946M | 9.019M | 5.04M |
| Net Income From Continuing Ops | -133.31M | -36.329M | -190.228M | -105.385M | -52.248M |
| Net Income Applicable To Common Shares | -133.31M | -36.329M | -190.228M | -105.385M | -52.248M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 621.827M | 787.648M | 814.658M | 488.251M | 421.913M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 16.946M | 10.997M | 7.071M | 8.203M | 4.364M |
| Total Liab | 487.669M | 573.206M | 513.934M | 220.721M | 227.17M |
| Total Stockholder Equity | 134.158M | 214.442M | 300.724M | 267.53M | 194.743M |
| Other Current Liab | 82.736M | -14.901M | -55.129M | 9.8M | -5.203M |
| Common Stock | 0.008M | 0.008M | 0.008M | 0.008M | 0.007M |
| Capital Stock | 0.008M | 0.008M | 0.008M | 0.008M | 0.007M |
| Retained Earnings | -710.078M | -579.687M | -446.377M | -410.048M | -219.82M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 7.881M | 7.046M | 4.089M | 2.148M |
| Cash | 74.555M | 154.323M | 329.152M | 49.969M | 89.641M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 177.948M | 45.578M | 48.218M | 44.202M | 31.805M |
| Current Deferred Revenue | 82.975M | 48.231M | 90.803M | 23.886M | 30.165M |
| Net Debt | -35.637M | -110.996M | -281.551M | 1.287M | -41.605M |
| Short Term Debt | 8.462M | 8.059M | 7.795M | 7.512M | 6.565M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 38.918M | 43.327M | 47.601M | 51.256M | 48.036M |
| Other Stockholder Equity | 844.044M | 798.696M | 748.036M | 676.956M | -7.499M |
| Property Plant Equipment | - | 53.332M | 27.33M | 30.181M | 62.328M |
| Total Current Assets | 565.807M | 726.435M | 749.713M | 421.511M | 357.437M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 474.306M | 558.528M | 406.099M | 363.339M | 263.432M |
| Net Receivables | - | 2.587M | 7.391M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 3.775M | 4.189M | 4.749M | 3.004M | 0.278M |
| Accumulated Other Comprehensive Income | 0.184M | -4.575M | -0.943M | 0.614M | 0.142M |
| Non Currrent Assets Other | 7.418M | 7.881M | 7.046M | 4.089M | 2.148M |
| Non Current Assets Total | 56.02M | 61.213M | 64.945M | 66.74M | 64.476M |
| Capital Lease Obligations | 38.918M | 43.327M | 47.601M | 51.256M | 48.036M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -159.014M | -46.416M | -100.019M | -33.609M | -224.119M |
| Total Cashflows From Investing Activities | -159.014M | -49.663M | -105.051M | -48.874M | -224.119M |
| Total Cash From Financing Activities | 4.514M | 30.295M | 232.113M | 172.353M | 131.146M |
| Net Income | -133.31M | -36.329M | -190.228M | -105.385M | -52.248M |
| Change In Cash | -174.829M | 279.183M | -39.672M | 24.171M | 34.491M |
| Begin Period Cash Flow | 330.624M | 51.441M | 91.113M | 66.942M | 32.451M |
| End Period Cash Flow | 155.795M | 330.624M | 51.441M | 91.113M | 66.942M |
| Total Cash From Operating Activities | -20.329M | 298.551M | -166.734M | -99.308M | 127.464M |
| Depreciation | 8.472M | 8.315M | 7.265M | 5.574M | 1.019M |
| Other Cashflows From Investing Activities | - | - | - | -33.609M | -222.235M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 2.448M |
| Sale Purchase Of Stock | - | 30.295M | 7.51M | 2.317M | -1.904M |
| Other Cashflows From Financing Activities | 1.455M | 30.295M | 7.51M | 2.225M | -224.119M |
| Capital Expenditures | 4.117M | 3.247M | 5.032M | 15.265M | 1.884M |
| Change In Working Capital | 59.526M | 283.681M | -15.222M | -12.274M | 174.362M |
| Other Non Cash Items | -1.163M | 2.099M | 0.929M | -3.504M | -2.594M |
| Free Cash Flow | -24.446M | 295.304M | -171.766M | -114.573M | 125.58M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | JPMorgan Small Cap Growth A | 7 months ago | 1491040 |
| 2. | Fidelity Growth Company K6 | 7 months ago | 1268931 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 1121407 |
| 4. | Fidelity Series Growth Company | 7 months ago | 949455 |
| 5. | Fidelity Small Cap Index | 8 months ago | 821665 |
| 6. | SPDR® S&P Biotech ETF | 6 months ago | 783011 |
| 7. | iShares Russell 2000 Growth ETF | 6 months ago | 724530 |
| 8. | BlackRock Advantage Small Cap Core Instl | 7 months ago | 667104 |
| 9. | Franklin Biotechnology Discv A(acc)USD | 7 months ago | 625636 |
| 10. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 547177 |
| 11. | iShares Biotechnology ETF | 6 months ago | 523794 |
| 12. | T. Rowe Price Health Sciences | 7 months ago | 504231 |
| 13. | Fidelity Extended Market Index | 7 months ago | 455556 |
| 14. | Vanguard Explorer Inv | 8 months ago | 416287 |
| 15. | Schwab US Small-Cap ETF™ | 6 months ago | 392152 |
| 16. | Fidelity Growth Compy Commingled Pl S | 7 months ago | 5115677 |
| 17. | Fidelity Growth Company Fund | 7 months ago | 3637369 |
| 18. | Fidelity Select Biotechnology | 7 months ago | 3535753 |
| 19. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 2365571 |
| 20. | iShares Russell 2000 ETF | 6 months ago | 2275940 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Deep Track Capital, LP | 8 months ago | 4631998 |
| 2. | FMR Inc | 8 months ago | 14595014 |
| 3. | BlackRock Inc | 11 months ago | 9101437 |
| 4. | Vanguard Group Inc | 8 months ago | 5455727 |
| 5. | Morgan Stanley - Brokerage Accounts | 8 months ago | 4355770 |
| 6. | JPMorgan Chase & Co | 8 months ago | 2728823 |
| 7. | State Street Corp | 8 months ago | 2616809 |
| 8. | BRAIDWELL LP | 8 months ago | 2158245 |
| 9. | Geode Capital Management, LLC | 8 months ago | 1903942 |
| 10. | Euclidean Capital LLC | 8 months ago | 1307858 |
| 11. | Soleus Capital Management, L.P. | 8 months ago | 1207371 |
| 12. | Deutsche Bank AG | 8 months ago | 1154337 |
| 13. | Deerfield Management Co | 8 months ago | 1055192 |
| 14. | Jacobs Levy Equity Management, Inc. | 8 months ago | 1017687 |
| 15. | Franklin Resources Inc | 8 months ago | 963484 |
| 16. | Baker Bros Advisors LP | 8 months ago | 927264 |
| 17. | Dafna Capital Management LLC | 8 months ago | 912928 |
| 18. | T. Rowe Price Associates, Inc. | 8 months ago | 816458 |
| 19. | Charles Schwab Investment Management Inc | 8 months ago | 760606 |
| 20. | Dimensional Fund Advisors, Inc. | 8 months ago | 724889 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...